# (R)-TTA-P2

**Cat. No.:** HY-10035A

**Molecular Formula:** $C_{21}H_{29}Cl_2FN_2O_2$

**Molecular Weight:** 431.37

**Target:** Others

**Pathway:** Others

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 50 mg/mL (115.91 mM; Need ultrasonic)

| Preparing Stock Solutions | Mass / Solvent / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.3182 mL | 11.5910 mL | 23.1820 mL |
| | 5 mM | 0.4636 mL | 2.3182 mL | 4.6364 mL |
| | 10 mM | 0.2318 mL | 1.1591 mL | 2.3182 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

(R)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease[1].

## REFERENCES

[1]. Chemin J, et al. De novo mutation screening in childhood-onset cerebellar atrophy identifies gain-of-function mutations in the CACNA1G calcium channel gene. Brain. 2018;141(7):1998-2013.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA